Affiliation:
1. Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi
2. NECMETTIN ERBAKAN UNIVERSITY, MERAM SCHOOL OF MEDICINE
3. Konya City Hospital
Abstract
Background: In the process of detecting cervical cancer, cytology and HPV genotype screening both play a significant part. More researches are required to determine whether or not multiple HPV genotyping can accurately predict cytological abnormalities.
Methods: A total of 696 female individuals were subjected to analysis for cytology and HPV genotype testing. HPV-DNA, smear and final pathology results of these patients and the relationship between them were investigated using statistical methods.
Results: Cytological data indicating abnormalities were seen in a total of 110 subjects. HPV-16 was determined to be the most prevalent variety among the patients, and HPV-16-positive females were found to have an elevated risk of cervical lesions. HPV 16 infection rates were substantially increased in patients with HSIL and higher lesions.
Conclusion: An infection caused by HPV-16 is a major risk factor for cervical lesions. A test that examines many HPV genotypes may be able to predict cytological problems.
Reference13 articles.
1. Arbyn M, Xu L. Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials. Expert review of vaccines. 2018;17(12):1085-91.
2. Bouvard V, Wentzensen N, Mackie A, Berkhof J, Brotherton J, Giorgi-Rossi P, et al. The IARC Perspective on Cervical Cancer Screening. The New England journal of medicine. 2021;385(20):1908-18.
3. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global health. 2020;8(2):e191-e203.
4. WHO Guidelines Approved by the Guidelines Review Committee. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. Geneva: World Health Organization© World Health Organization 2021.; 2021.
5. Bruni L, Serrano B, Roura E, Alemany L, Cowan M, Herrero R, et al. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. The Lancet Global health. 2022;10(8):e1115-e27.